Kling Bio has announced a new collaboration and licence option agreement with Sanofi to accelerate the discovery of neutralising antibodies using its proprietary B cell platform, Kling-Select.
The partnership will focus on identifying monoclonal antibodies with potent neutralising activity against a clinically relevant human viral pathogen. The findings may support the development of next-generation antiviral therapies and inform future vaccine design.
Kling-Select is a clinically and commercially validated B cell immortalisation and screening platform. It uses patient-derived B cells to rapidly identify novel antibodies and conserved viral epitopes, enhancing vaccine and therapeutic design.
The platform’s function-first screening workflow enables the discovery of rare, immuno-functional antibodies. It has already yielded validated candidates against RSV, COVID-19 and influenza, demonstrating its broad utility and scientific impact.
Michael Koslowski, MD, Chief Executive Officer of Kling Bio, said: “This collaboration with Sanofi highlights the broad potential of our Kling-Select platform to address global health challenges by enabling the discovery of first-in-class, human-derived antibodies.”
He added: “Kling-Select provides a powerful window into the human immune response and accelerates the identification of functional antibodies and novel epitopes. We are excited to combine our expertise with Sanofi’s leadership in vaccine development to advance next-generation therapeutics and vaccines.”
The collaboration underscores Kling’s commitment to transforming disease prevention and treatment through advanced antibody discovery technologies.
